Annovis Bio, Inc.

ANVS XNYS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

79M

Short interest (May 15)

13.5%

Net Short (Jun 03 ): 0.1%

Borrow Fee

0.93%

↓ 8.9%

Available Shares

↑ 264.1%

Price Chart

Company Overview

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Company Info

Exchange: NYSE

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001477845

Asset Type: CS

Market Data

Market Cap: $79,127,874

Employees: 7

Status: Active

Short Interest

Current Borrow Fee 0.93%

Range: 0.93% - 1.43%

Available Shares 2M

Range: 1.5M - 1.6M

Recent Changes

Fee Change: ↓ 34.5%

Available Change: ↓ 9.1%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime